{"id":60908,"date":"2025-03-10T22:02:35","date_gmt":"2025-03-10T21:02:35","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/hinge-health-files-registration-statement-for-proposed-initial-public-offering\/"},"modified":"2025-03-10T22:02:35","modified_gmt":"2025-03-10T21:02:35","slug":"hinge-health-files-registration-statement-for-proposed-initial-public-offering","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/hinge-health-files-registration-statement-for-proposed-initial-public-offering\/","title":{"rendered":"Hinge Health Files Registration Statement for Proposed Initial Public Offering"},"content":{"rendered":"
\n

SAN FRANCISCO–(BUSINESS WIRE)–Hinge Health announced that it has filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission (SEC) relating to a proposed initial public offering of its Class A common stock. The number of shares to be offered and the price range for the proposed offering have not yet been determined. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.\n<\/p>\n

<\/a>
<\/a><\/p>\n

\nHinge Health intends to list its Class A common stock on the New York Stock Exchange under the ticker symbol \u201cHNGE.\u201d\n<\/p>\n

\nMorgan Stanley, Barclays and BofA Securities are acting as lead book-running managers for the proposed offering. Evercore ISI, RBC Capital Markets, Truist Securities, Stifel, William Blair, Piper Sandler, Canaccord Genuity, KeyBanc Capital Markets, Needham & Company, Raymond James, and KKR Capital Markets LLC are also acting as book-running managers.\n<\/p>\n

\nThe proposed offering will be made only by means of a prospectus. Copies of the preliminary prospectus, when available, may be obtained from: Morgan Stanley & Co. LLC, Attention: Prospectus Department, 180 Varick Street, 2nd Floor, New York, New York 10014, or email: prospectus@morganstanley.com<\/a>; Barclays Capital Inc., c\/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, New York 11717, by email: barclaysprospectus@broadridge.com<\/a>, or by telephone: (888) 603-5847; or BofA Securities, Inc., NC1-022-02-25, 201 North Tryon Street, Charlotte, North Carolina 28255-0001, Attention: Prospectus Department, by email: dg.prospectus_requests@bofa.com<\/a>, or by telephone: (800) 294-1322.\n<\/p>\n

\nA registration statement relating to these securities has been filed with the SEC but has not yet become effective. These securities may not be sold, nor may offers to buy be accepted, prior to the time the registration statement becomes effective. This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.\n<\/p>\n

\nAbout Hinge Health<\/b>\n<\/p>\n

\nHinge Health leverages software, including AI, to largely automate care for joint and muscle health, delivering an outstanding member experience, improved member outcomes, and cost reductions for its clients. The company has designed its platform to address a broad spectrum of MSK care\u2014from acute injury, to chronic pain, to post-surgical rehabilitation\u2014and the platform can help to ease members\u2019 pain, improve their function, and reduce their need for surgeries, all while driving health equity by allowing members to engage in their exercise therapy sessions from anywhere. The company is headquartered in San Francisco, California.\n<\/p>\n

Contacts<\/b> <\/p>\n

\nMedia Contact: <\/b>media@hingehealth.com<\/a>\n<\/p>\n

\nInvestor Relations Contact: <\/b>ir@hingehealth.com<\/a>\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

SAN FRANCISCO–(BUSINESS WIRE)–Hinge Health announced that it has filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission (SEC) relating to a proposed initial public offering of its Class A common stock. The number of shares to be offered and the price range for the proposed offering have not yet been … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-60908","6":"format-standard","7":"category-industry"},"yoast_head":"\nHinge Health Files Registration Statement for Proposed Initial Public Offering - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/hinge-health-files-registration-statement-for-proposed-initial-public-offering\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Hinge Health Files Registration Statement for Proposed Initial Public Offering - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"SAN FRANCISCO–(BUSINESS WIRE)–Hinge Health announced that it has filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission (SEC) relating to a proposed initial public offering of its Class A common stock. The number of shares to be offered and the price range for the proposed offering have not yet been ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/hinge-health-files-registration-statement-for-proposed-initial-public-offering\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2025-03-10T21:02:35+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20250310050089\/en\/2405191\/22\/Hinge_Health_Logo_Horizontal_Green_%282%29.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/hinge-health-files-registration-statement-for-proposed-initial-public-offering\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/hinge-health-files-registration-statement-for-proposed-initial-public-offering\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Hinge Health Files Registration Statement for Proposed Initial Public Offering\",\"datePublished\":\"2025-03-10T21:02:35+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/hinge-health-files-registration-statement-for-proposed-initial-public-offering\\\/\"},\"wordCount\":479,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/hinge-health-files-registration-statement-for-proposed-initial-public-offering\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20250310050089\\\/en\\\/2405191\\\/22\\\/Hinge_Health_Logo_Horizontal_Green_%282%29.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/hinge-health-files-registration-statement-for-proposed-initial-public-offering\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/hinge-health-files-registration-statement-for-proposed-initial-public-offering\\\/\",\"name\":\"Hinge Health Files Registration Statement for Proposed Initial Public Offering - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/hinge-health-files-registration-statement-for-proposed-initial-public-offering\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/hinge-health-files-registration-statement-for-proposed-initial-public-offering\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20250310050089\\\/en\\\/2405191\\\/22\\\/Hinge_Health_Logo_Horizontal_Green_%282%29.jpg\",\"datePublished\":\"2025-03-10T21:02:35+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/hinge-health-files-registration-statement-for-proposed-initial-public-offering\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/hinge-health-files-registration-statement-for-proposed-initial-public-offering\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/hinge-health-files-registration-statement-for-proposed-initial-public-offering\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20250310050089\\\/en\\\/2405191\\\/22\\\/Hinge_Health_Logo_Horizontal_Green_%282%29.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20250310050089\\\/en\\\/2405191\\\/22\\\/Hinge_Health_Logo_Horizontal_Green_%282%29.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/hinge-health-files-registration-statement-for-proposed-initial-public-offering\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Hinge Health Files Registration Statement for Proposed Initial Public Offering\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Hinge Health Files Registration Statement for Proposed Initial Public Offering - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/hinge-health-files-registration-statement-for-proposed-initial-public-offering\/","og_locale":"en_US","og_type":"article","og_title":"Hinge Health Files Registration Statement for Proposed Initial Public Offering - Pharma Trend","og_description":"SAN FRANCISCO–(BUSINESS WIRE)–Hinge Health announced that it has filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission (SEC) relating to a proposed initial public offering of its Class A common stock. The number of shares to be offered and the price range for the proposed offering have not yet been ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/hinge-health-files-registration-statement-for-proposed-initial-public-offering\/","og_site_name":"Pharma Trend","article_published_time":"2025-03-10T21:02:35+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20250310050089\/en\/2405191\/22\/Hinge_Health_Logo_Horizontal_Green_%282%29.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/hinge-health-files-registration-statement-for-proposed-initial-public-offering\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/hinge-health-files-registration-statement-for-proposed-initial-public-offering\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Hinge Health Files Registration Statement for Proposed Initial Public Offering","datePublished":"2025-03-10T21:02:35+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/hinge-health-files-registration-statement-for-proposed-initial-public-offering\/"},"wordCount":479,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/hinge-health-files-registration-statement-for-proposed-initial-public-offering\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20250310050089\/en\/2405191\/22\/Hinge_Health_Logo_Horizontal_Green_%282%29.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/hinge-health-files-registration-statement-for-proposed-initial-public-offering\/","url":"https:\/\/pharma-trend.com\/en\/hinge-health-files-registration-statement-for-proposed-initial-public-offering\/","name":"Hinge Health Files Registration Statement for Proposed Initial Public Offering - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/hinge-health-files-registration-statement-for-proposed-initial-public-offering\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/hinge-health-files-registration-statement-for-proposed-initial-public-offering\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20250310050089\/en\/2405191\/22\/Hinge_Health_Logo_Horizontal_Green_%282%29.jpg","datePublished":"2025-03-10T21:02:35+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/hinge-health-files-registration-statement-for-proposed-initial-public-offering\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/hinge-health-files-registration-statement-for-proposed-initial-public-offering\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/hinge-health-files-registration-statement-for-proposed-initial-public-offering\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20250310050089\/en\/2405191\/22\/Hinge_Health_Logo_Horizontal_Green_%282%29.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20250310050089\/en\/2405191\/22\/Hinge_Health_Logo_Horizontal_Green_%282%29.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/hinge-health-files-registration-statement-for-proposed-initial-public-offering\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Hinge Health Files Registration Statement for Proposed Initial Public Offering"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/60908","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=60908"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/60908\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=60908"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=60908"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=60908"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}